1312937-41-9

Usage

Uses

Used in Pharmaceutical Industry:
Erlotinib IMpurity C is used as a reference standard for quality control and analytical testing purposes in the pharmaceutical industry. It helps ensure the purity, potency, and safety of Erlotinib, a medication used to treat various types of cancer, including non-small cell lung cancer, pancreatic cancer, and head and neck cancer.
Erlotinib IMpurity C is used as a research tool for studying the mechanism of action, metabolism, and potential side effects of Erlotinib. This helps researchers and pharmaceutical companies to optimize the drug's efficacy and minimize adverse effects, ultimately contributing to the development of better cancer treatments.

Upstream product

• 183322-18-1 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline 
• 16064-15-6 6,7-dihydroxyquinazolin-4(3H)-one 
• 4101-33-1 6,7-dimethoxy-N,N-quinazoline 
• 179688-29-0 6,7-bis(2-methoxyethoxy)-3,4-dihydroquinazolin-4-one 
• 67-56-1 methanol 
• 1312937-40-8 4-methoxyquinazoline-6,7-diol 
• 6482-24-2 2-Bromoethyl methyl ether 

Downstream Products

• 183319-69-9 erlotinib hydrochloride 
• 183321-74-6 erlotinib 

Relevant academic research and scientific papers

Preparation process of erlotinib

Preparation process of erlotinib or its salts comprising: reacting 6,7-bis(2-methoxyethoxy)-4-methoxyquinazoline with 3-ethynylaniline or a salt thereof in the presence of a base and a reaction-inert solvent, and optionally, treating the compound obtained with a pharmaceutically acceptable acid to form the corresponding pharmaceutically acceptable salt. The compound 6,7-bis(2-methoxyethoxy)-4-methoxyquinazoline can be prepared either from 4-methoxyquinazoline-6,7-diol or 6,7-bis(2-methoxyethoxy)quinazolinone. The compounds 6,7-bis(2-methoxyethoxy)-4-methoxyquinazoline and 4-methoxyquinazoline-6,7-diol are new intermediates useful for the preparation of erlotinib or its salts.

PREPARATION PROCESS OF ERLOTINIB

Preparation process of erlotinib or its salts comprising: reacting 6,7-bis(2-methoxyethoxy)-4-methoxyquinazoline with 3-ethynylaniline or a salt thereof in the presence of a base and a reaction-inert solvent, and optionally, treating the compound obtained with a pharmaceutically acceptable acid to form the corresponding pharmaceutically acceptable salt. The compound 6,7-bis(2-methoxyethoxy)-4-methoxyquinazoline can be prepared either from 4-methoxyquinazoline-6,7-diol or 6,7-bis(2-methoxyethoxy)quinazolinone. The compounds 6,7-bis(2-methoxyethoxy)-4-methoxyquinazoline and 4-methoxyquinazoline-6,7-diol are new intermediates useful for the preparation of erlotinib or its salts.